Skip to content

WSI Based DL for Diagnosing the IASLC Grading System of Lung Adenocarcinoma

Whole Slide Image Based Deep Learning for Diagnosing the International Association for the Study of Lung Cancer Proposed Grading System of Lung Adenocarcinoma

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05925764
Enrollment
200
Registered
2023-06-29
Start date
2024-10-15
Completion date
2024-12-31
Last updated
2024-10-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Artificial Intelligence, IASLC Grading System, Lung Adenocarcinoma, Whole Slide Image

Brief summary

The purpose of this study is to evaluate the performance of a whole slide image based deep learning model for diagnosing the IASLC grading system in resected lung adenocarcinoma based on a multicenter prospective cohort.

Interventions

DIAGNOSTIC_TESTWhole Slide Image based Deep Learning

Whole Slide Image Based Deep Learning for Diagnosing the IASLC Grading System of Lung Adenocarcinoma

Sponsors

Shanghai Pulmonary Hospital, Shanghai, China
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years

Inclusion criteria

1. Age ranging from 18-85 years old; 2. Pathological confirmation of primary lung adenocarcinoma after surgery; 3. Obtained written informed consent.

Exclusion criteria

1. Multiple lung lesions; 2. Poor quality of whole slide images; 3. Mucinous adenocarcinomas and variants; 4. Participants who have received neoadjuvant therapy.

Design outcomes

Primary

MeasureTime frameDescription
Agreement rate of the IASLC grading system2024.11.01-2024.12.31Agreement rate between the deep learning model and pathologists in diagnosing the IASLC grade of lung adenocarcinoma.

Secondary

MeasureTime frameDescription
Agreement rate of the predominant subtypes2024.11.01-2024.12.31Agreement rate between the deep learning model and pathologists in diagnosing the predominant growth patterns of lung adenocarcinoma.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026